Malaria drug succeeds in large clinical trial, effective against resistant strains

A new antimalarial drug has produced encouraging results in a large, multi-country clinical trial, offering hope as malaria parasites continue to evolve resistance to long-standing treatments. Scientists and public health officials see the findings as a potentially important step toward keeping malaria under control across Africa and other high-burden regions.

Developed as a different class of therapy from the widely used artemisinin combinations, the candidate—known as KLU156—was tested in more than a thousand patients across a dozen African nations. The trial’s outcomes suggest it could become a vital tool in the global fight against a disease that still claims hundreds of thousands of lives each year.

KLU156: a new option that isn’t artemisinin-based

KLU156 combines a novel molecule, ganaplacide, with lumefantrine—the same partner drug used in many current Artemisinin-based Combination Therapies (ACTs). Rather than relying on traditional botanical leads, the compound was discovered through advanced computational screening of millions of molecules by Novartis researchers. That is how ganaplacide emerged as a promising antimalarial candidate.

The rise of ACTs began after the extraction and development of artemisinin from sweet wormwood, work that earned Tu Youyou a Nobel Prize and established artemisinin-based regimens as the global standard since the early 2000s. But with signs of artemisinin resistance increasing in several regions, finding non-artemisinin alternatives has become a public-health priority.

Trial results: strong cure rates and measurable benefits

The phase of testing presented to peers at the American Society of Tropical Medicine and Hygiene evaluated KLU156 in roughly 1,600 patients from 12 African countries. Key outcomes included:

• 99.2% cure rate for those treated with KLU156 (ganaplacide + lumefantrine).
• 96.7% cure rate for the comparison group treated with lumefantrine-based therapy alone.
• A difference of about 2.5 percentage points, which translates into many lives saved when applied across high-burden populations.

Researchers emphasize that while the percentage gap may seem small, the absolute impact is large when malaria infects millions annually and causes a substantial death toll across Africa.

Impact on transmission and parasite stages

Beyond clinical cure, KLU156 showed activity against the parasite stage that mosquitoes pick up when biting infected humans. That reproductive phase is crucial for continuing the transmission cycle.

By reducing the number of parasites capable of infecting mosquitoes, the drug could lower onward transmission and help interrupt chains of infection—a valuable feature for public-health programs seeking not just to treat illness but to limit spread.

Side effects and formulation challenges

No medicine is without trade-offs. The trial flagged tolerability issues that will need fixing before widespread use:

• Patients reported a notably unpleasant taste to the dose, which is delivered as a powder to be dissolved in water.
• This taste was associated with about 20% more episodes of vomiting compared with the comparator group.
• Vomiting led to roughly ten times more treatment interruptions among those receiving KLU156.

Novartis and collaborators are investigating ways to mask the flavor or alter the formulation to reduce vomiting and improve adherence.

Regulatory plans and pricing intentions

Novartis has indicated plans to seek regulatory approval as quickly as possible if follow-up studies continue to support safety and efficacy. The company has also signaled an intention to make the drug available at cost in low-income settings, should it reach licensing and distribution.

When and how to use KLU156: policy considerations

Public-health experts are debating the optimal strategy for deploying KLU156 once approved. Two central concerns guide the discussion:

• KLU156 includes lumefantrine, the same partner drug used in ACTs, which raises questions about cross-resistance if lumefantrine efficacy declines.
• There is already evidence that Plasmodium falciparum and Plasmodium vivax strains have developed resistance to artemisinin in some areas, which could accelerate pressure on partner drugs.

One proposal under consideration—reported in scientific outlets covering the trial—is a seasonal rotation approach:

1. Use KLU156 at the start of a malaria season to tackle early transmission and cases.
2. Follow with conventional ACTs in the next season.
3. Alternate between the two approaches over successive seasons to limit the selective pressure that drives resistance.

Researchers caution that any rollout strategy must weigh immediate public-health gains against long-term stewardship of antimalarial drugs. The debate is further complicated by the argument that withholding a highly effective new treatment could be unethical where patients currently suffer and die from malaria.

Voices from the field and next steps

Field investigators involved with the study described the findings as highly encouraging, noting the urgency created by rising resistance trends. One Malian scientist working on the trial said that discovering a safe, non-artemisinin option that performs well in the clinic is a major development for malaria control efforts.

Planned next steps include refining the drug’s formulation to improve tolerability, submitting data for regulatory review, and conducting additional studies to guide optimal use in various epidemiological settings. Research teams and public-health authorities will need to coordinate on deployment policies that preserve the drug’s effectiveness while delivering immediate benefits to populations at greatest risk.

You might also like:

• Papua New Guinea malaria deaths fall 92% despite no vaccine
• Southeast Asia malaria nears elimination as cases fall two-thirds since 2010
• HIV transmission prevented 100% by twice-yearly lenacapavir injection in trial
• Breakthrough Cancer Treatment: Retooled Drugs Wipe Out Aggressive Tumors in New Trial!
• Dengue risk cut 70% after infecting mosquitoes with natural bacteria in citywide trial

Michael Thompson

Michael Thompson is an experienced journalist covering U.S. and global news. With ten years on the front lines, he breaks down political and economic stories that matter. His precise writing and keen attention to detail help you grasp the real‑world impact of every event.